Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MCAO mice showed overexpression of interleukin-6 (IL-6), IL-17, and IL-23, and increased positive protein expression of PTGS2, as well as expression of PTGS2, nuclear factor-κB (NF-κB), tumor suppressor region 1 (TSP-1) and Bcl-2-associated X protein (Bax), but underexpression of vascular endothelial growth factor (VEGF), S-phase kinase associated protein 2 (Skp2), and B-cell lymphoma 2 (Bcl-2).
|
31222746 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To circumvent this, here we employ adeno-associated virus (AAV) gene therapy vectors to express 3TSR alone or in combination with the CD47-binding peptide of TSP-1 and evaluate the impact on tumor development and survival in a mouse model of EOC.
|
31160686 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Despite that LDMC induced TSP1 mRNA expression, and the hypoxic area in the tumors was slightly increased, no decrease in MVD was detected.
|
29299975 |
2018 |
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TSP1 levels in the tumour stroma were negatively correlated with vascular indoleamine 2,3-dioxygenase 1 (IDO1) in IDC tissues.
|
29156701 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dysfunction of Rab37 or loss of TSP1 abrogated the suppressive effects on angiogenesis and metastasis.<b>Conclusions:</b> Our findings suggest that Rab37-mediated TSP1 secretion in cancer cells suppresses metastasis and angiogenesis via a cross-talk with endothelial cells and reveal a novel component of the vesicular exocytic machinery in tumor microenvironment and tumor progression.
|
28151721 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor angiogenesis is driven by a complex interplay between pro-angiogenic (VEGF/VEGFR, PDGF/PDGFR) and anti-angiogenic factors (TSP-1/TSP-2) within the tumor microenvironment.
|
27376737 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This observation was confirmed after adjusting the results for age and tumor grade, the role of TSP-1 being most pronounced in oligodendrogliomas (p = 0.001).
|
25621889 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We propose the establishment of an IHC test to calculate the score of TrpRS, DP, and TSP1 in TNBC tumors to evaluate the degree of aggressiveness of the tumors.
|
26209610 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, T-oligo decreases tumor size and inhibits angiogenesis through decreased VEGF signaling and increased TSP-1 expression.
|
24041868 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several reports suggest that TSP-1 possesses tumour suppressor function, through its ability to inhibit tumour neovascularization.
|
22207555 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thrombospondin-2 (TSP-2) has been shown to inhibit tumor growth and angiogenesis with a greater potency than the related molecule TSP-1.
|
20714802 |
2011 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of Tsp-1 was most consistently and robustly diminished in medulloblastoma cell lines and primary human tumors with high Myc expression (n = 101, P = 0.032).
|
20876797 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although Snail(+) melanoma did not respond to immunotherapy, intratumoral injection with snail-specific siRNA or anti-TSP1 monoclonal antibody significantly inhibited tumor growth and metastasis following increase of tumor-specific tumor-infiltrating lymphocytes and systemic immune responses.
|
19249678 |
2009 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TSP-1 inhibited tumor cell-induced neoangiogenesis by directly sequestering the proangiogenic factor VEGF, and inactivating the angiogenesis initiated by VEGFR2 phosphorylation in endothelial cells.
|
19805200 |
2009 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Induction of TSP-1 mRNA by TGF-beta was attenuated by c-Ski in vitro, and expression of TSP-1 mRNA was decreased in tumors expressing c-Ski in vivo.
|
19594546 |
2009 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By comparing the expression of p53, cyclin D1, p16, hTERT, and TSP-1 in spontaneously regressing keratoacanthoma (KA) as a paradigm of early neoplasia, with malignant invasive cutaneous squamous cell carcinoma (SCC) as a paradigm of advanced tumour development, we are now able to assign the changes in the expression of these proteins to specific stages and allocate them to defined roles in the multi-step process of skin carcinogenesis.
|
17198740 |
2007 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-18 and TSP-1 are related to tumor proliferation and metastasis.
|
16650813 |
2006 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
RASSF1A was also methylated in 70% of the primary NB tumors tested, and TSP-1 methylation was detected in 55% of the tumors.
|
15623630 |
2004 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The importance of down-regulation of TSPs for tumor progression is further established by the fact that several different approaches that are designed to increase the levels of TSP-1 or -2 in tumor tissue inhibit tumor growth.
|
15094119 |
2004 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
TSP-1 promoter methylation was detected in all of the NB cell lines lacking TSP-1 mRNA and in 37% of the NB clinical tumors analyzed.
|
14559817 |
2003 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite this clear reduction in tumor vascularity, the tumor perfusion was the same in TSP-1-transfected tumors and controls.
|
11861403 |
2002 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In several tumors (thyroid, colon, bladder carcinomas), TSP1 expression is inversely correlated with tumor grade and survival rate, whereas in others (e.g. breast carcinomas), it is correlated with the stromal response and is of little prognostic value.
|
11530335 |
2001 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TSP-1 was suggestive for improved survival in patients with advanced disease; high TSP-1 expression was associated with a median survival of 2.4 years compared to 1.5 years for patients with tumors having a lower degree of TSP-1 expression (P = 0.06).
|
11531279 |
2001 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TSP-1 immunoreactivity was detected in the extracellular matrix, mostly at the invasion front of the tumor.
|
11253112 |
2001 |